INTRODUCTION
After more than two decades of escalating morbidity and mortality stemming from the opioid epidemic in the United States, early signs suggest that specific mitigating interventions are taking hold to lessen deleterious public health impacts. Declared public health emergencies at every level of government have led to legal reforms to monitor the crises and infuse essential resources.
1 Extensive public education campaigns targeting health care workers and patients have significantly raised risk awareness.
(e.g., physical therapy), 12 or still under development (e.g., tanezumab).
13
Another primary alternative to treat Americans' pains is emerging: marijuana.
14 Like opioids, marijuana and its varied derivatives have grown exponentially since first being authorized for medical use in California in 1996. 15 Even though federal authorities still disapprove the drug for any purpose, thirty-three states and the District of Columbia now allow medical marijuana 16 for a range of conditions, including palliative care. 17 Despite thin proof of efficacy for treating many conditions, multiple states are pushing medical marijuana as a suitable substitute for prescription opioids to address pain as well as opioidrelated use disorders. 18 Critical issues of public health law and policy arise from the displacement of opioid drugs in favor of medical marijuana. While these two classes of drugs are similarly intended to manage pain, their legality and public health impacts are highly divergent and subject to public misperceptions of their safety and effective use. 19 Promoting marijuana over opioids is risky given substantial uncertainties over short-and longterm impacts of its widespread use. 20 Even as the nation slowly exits the 14. See generally NAT'L ACADS. OF long tunnel of the opioid crises, it may be heading into a fog of extensive, additional public health repercussions.
I. SHIFTING EPIDEMIOLOGY AND LEGAL RESPONSES TO THE OPIOID EPIDEMIC
Americans' modern addiction to opioids of all types began in the 1990s with the over-prescribing of new and lawful opioid drugs largely to treat their short-or long-term pain. 21 Pushed by major pharmaceutical companies as a viable alternative to less effective pain treatments, prescription opioids became commonplace.
22
With their rise came stealthy public health impacts. The same qualities of prescription opioids that render them effective in mediating pain responses in the brain 23 can also facilitate addiction.
24
Relaxed oversight of opioid prescribing coupled with an under-appreciation of their addictive properties have inflated prescription practices, driven massive rates of addiction, and led to substantial morbidity and mortality from prescription opioid abuses and overdoses. 25 Nearly 220,000 Americans have died from their misuse of prescription opioids over the last two decades. 26 28 Their reluctance to adequately treat patients' pain generated ethical arguments focused on patient autonomy and diminished quality of life. 29 Beginning in the 1980s, select researchers suggested that opioids could be prescribed safely with only minimal risks to patients of developing substance use disorders. 30 By the late 1990's, the American Medical Association 31 and the American Pain Society 32 were advocating for greater recognition and assessment of pain in the clinic. Purdue Pharma released OxyContin in 1996 with an aggressive marketing and physician education campaign. 33 The federal Department of Veterans Affairs (VA) adopted "Pain as 5th Vital Sign" in 1999, requiring quantitative assessments of pain for all patients. 34 By 2001, the Joint Commission on Accreditation of Healthcare Organizations implemented new standards requiring practitioners at accredited hospitals to more fully evaluate and treat pain. 35 From 1997 to 2007 opioid prescriptions swelled 700% with an accompanying rise in mortality. 36 Millions of other patients were accessing prescription opioids in greater doses and quantities. The median size of each opioid prescription more than doubled from 2000 to 2010.
37 At the apex of the epidemic (see Figure 1 below), sixty-two million opioid prescriptions were filled in the final quarter of 2012 alone. 38 In 2015, 38% of Americans used prescription opioids for pain. Significant rises in mortality alarmed public health, law enforcement, and safety officials at all levels of government. 42 In 2014, the federal Drug Enforcement Administration (DEA) elevated hydrocodone combination opioids from Schedule III to II via the Controlled Substances Act (CSA), 43 which sharply decreased prescription rates of these drugs. 44 The Centers for Disease Control and Prevention (CDC) 41 . Information for this figure is adapted from publicly available CDC data published online. published national prescribing guidelines for opioids in 2016, recommending lower dosing regimens, risk assessments for all patients, and properly-timed termination of opioid therapy. 45 In 2017, the Food and Drug Administration (FDA) requested Endo Pharmaceuticals to completely withdraw a high-risk prescription opioid from the market.
46
FDA further required drug companies to educate providers on safely prescribing opioids and considering alternatives. 47 The Department of Justice (DOJ) began to crack down on unscrupulous pill mills, prosecuting hundreds of providers.
48
On October 26, 2017, the Department of Health and Human Services (HHS) declared the opioid epidemic a national public health emergency, 49 which it has renewed three times for ninety-day periods.
50
States have also responded extensively to rising prescription rates. Figure 1 , after peaking between 2010 and 2012, prescription rates decreased by over 13% by 2015 61 and remained in decline through 2017. 62 The VA reports that 99% of their hospital systems decreased their prescribing rates between 2012 and 2018, some by upwards of 70%. 63 Purdue Pharma released a full page advertisement in the New York Times on August 1, 2018 stating "[w]e are acutely aware of the public health risks opioid analgesics can create, even when taken as prescribed" and detailing their responses including "provid[ing] funding . . . to distribute the overdose rescue drug naloxone." 64 One national poll determined that 46% of Americans not prescribed opioids in 2016 expressed concerns about the use of prescription opioids, up from 30% in 2011. 65 Substantial efforts to reduce prescribing rates of opioids, however, have generated significant costs via substance abuse treatments 66 and concerns among physicians and patients regarding access to effective palliative treatments for patients with intermittent or chronic pain. 67 
II. ESCALATION OF MEDICAL MARIJUANA
Quelling prescription opioid use is about saving lives, not denying access to palliative care. Consequently, public health officials, medical practitioners, and patients are seeking opioid alternatives to address pain. 68 General anti-inflammatory medications (e.g. ibuprofen) are cheap but considerably less potent. 69 Physical therapy is often prohibitively expensive or cumbersome for some patients to complete. 70 Some providers are using therapeutics outside of manufacturer recommendations (e.g. spinal corticosteroid injections) with associated adverse consequences. 71 Additional pain treatment options (e.g. nerve growth factor inhibitors, slow-release post-surgical anesthetics) are in development but currently unapproved.
72
The imminent need for alternative palliative treatments is leading many patients and providers to consider marijuana as a viable option. 73 While medicinal use of cannabis date back thousands of years, 74 Figure 2 , marijuana use in the U.S. has risen over the last decade across all age groups (especially persons aged 18-29 years). In most states, medical marijuana may be authorized only to treat specific ailments. Laws vary as to whether patients may cultivate cannabis at home or are limited to accessing it through licensed dispensaries.
79
Ten jurisdictions also permit recreational uses of marijuana, essentially allowing persons to acquire and use marijuana for any purpose. Evolution of state marijuana policies contravene federal marijuana prohibitions. 82 As a CSA Schedule I drug, marijuana (like heroin) is viewed as having a high potential for abuse and no safe or effective medical uses. 83 excuse prior convictions for mere possession or use of marijuana. 94 Despite its convoluted legal status, marijuana is known as an effective treatment for symptoms of conditions including HIV/AIDS and cancer. 95 Some studies suggest that marijuana is a viable treatment for symptoms of multiple sclerosis, Tourette syndrome, anxiety, epilepsy, and posttraumatic stress disorder. 96 In 2017, the National Academies found "substantial evidence" that marijuana (and its subcomponents) can also help alleviate chronic pain. 97 However, efficacy of marijuana as a palliative drug is not fully proven. While opioids are effective "pain killers," marijuana is more like a "pain distracter." 98 Still, Americans appear poised to substitute marijuana in place of opioids. One study suggests that states permitting medical cannabis (especially jurisdictions with dispensaries) saw significantly lower daily opioid prescriptions compared to states that do not permit marijuana. 99 Ultimately, the viability of medical marijuana as an opioid alternative may turn on its safety, although a lack of reliable public health surveillance and research may discount potential short-and longterm risks of marijuana use. Marijuana may not contribute substantially to overdose-related deaths, 100 but available research has uncovered detrimental harms to users. Well-known side effects of acute cannabis use include "impairment in the cognitive domains of learning, memory, and attention," 101 as well as sleepiness, confusion, and tachycardia (rapid heart rate). 102 Effects of long-term use, however, could be far more precarious. There is substantial evidence 103 that effects of prolonged marijuana use may include increased risks of respiratory disease complications (e.g., for chronic bronchitis), vehicular collisions, and schizophrenia (as well as other forms of psychosis), 104 with moderate evidence 105 of dependence and substance use disorders related to alcohol, tobacco, and other illicit drugs. 106 Impacts of marijuana use among youth may be especially profound. Studies demonstrate that early-onset marijuana use in youth and young adults detrimentally impairs cognitive function and IQ score. 107 Even though many states require package warning labels against marijuana use among pregnant and breast-feeding women, 108 prenatal cannabis use is on the rise. 109 THC can cross the placental barrier, adversely impacting "fetal and postnatal brain development [and] neuronal connectivity." 110 
III. TRANSITIONING FROM OPIOIDS TO MARIJUANA
National and state public health efforts to diminish prescription opioids share the immediate objective of reducing preventable deaths stemming from opioid addictions. Whether these laudable policies are properly motivated in the interests of the public's health is beyond debate. Nor is it a matter of denying patients access to available and effective palliative care alternatives. The most pertinent question is whether anti-opioid policies may lead to other public health repercussions impacting the same or different populations affected by widespread prescription opioid use. Specifically, is the substitution of marijuana as a viable alternative to prescription opioids an effective, long-term public health strategy, 111 or just another wrong turn on the road to treating Americans' physical and mental pains?
These issues are percolating against the backdrop of states' latest directives in the battle over widespread opioid uses. Over two million Americans with known opioid use disorders (OUDs) are receiving specialized treatment interventions;
112 millions more likely need treatment now (or will soon) as opioid reduction strategies progress. 113 Multiple state policymakers propose marijuana not just as a viable palliative care option, but also as a potential drug to help ameliorate the symptoms of opioid withdrawal. 114 Under this view, marijuana is not merely an alternative to treating Americans' underlying sources of pain, but also for their newfound medical needs stemming from opioid withdrawals.
To address the underlying issue of chronic pain, several states have added chronic or intractable pain as qualifying conditions for medical cannabis. 115 In 2018, three states (NJ, NY, PA) explicitly added opioid use disorder to their indications for obtaining medical marijuana. 116 In January 2018, New Jersey Governor Phil Murphy prompted the state's Department of Health to review its medical cannabis program. In an Executive Order, he intimated that increased access to medical marijuana would make patients "less likely to turn to potentially more harmful and less medically appropriate drugs such as opioids." 117 Two months later, the Department announced that "chronic pain conditions that are related to musculoskeletal disorders" would qualify patients for medical marijuana.
118 Health officials later confirmed that this category includes OUDs arising from the treatment of chronic pain with opioids.
119
In May 2018, the Pennsylvania Department of Health moved to provide access to medical marijuana for OUDs and authorized university research on medicinal uses for cannabis. 120 Its rule explicitly denotes opioid use disorder as a qualifying condition for marijuana, 121 whether or not the disorder resulted from traditional pain management. However, justifying a prescription for medical marijuana still requires that "conventional therapeutic interventions [for opioid use disorder] are contraindicated or ineffective" or that cannabis is used in concert with another therapeutic. 122 According to Pennsylvania's Secretary of Health, Dr. Rachel Levine, while cannabis cannot replace established interventions for opioid use disorder, the shift would "give physicians another tool for treatment of this devastating disease." 123 On July 12, 2018, New York State approved even broader access to marijuana in responding to the opioid crisis. 124 Its new rules signaled that marijuana may be a suitable substitute for "pain that degrades health and functional capability where the use of medical marijuana is an alternative to opioid use, provided that the precise underlying condition is expressly stated on the patient's certification." 125 New York State added opioid use disorder as one condition to use medical cannabis so long as patients participate in a certified treatment program. 126 Essentially, marijuana may be given to patients suffering not only from OUDs, but also any other condition for which an opioid may have been prescribed. Moreover, New York's rule does not mandate exhaustion of other treatment options prior to allowing medical marijuana. 127 The New York Department of Health simultaneously recommended that the State authorize regulated recreational uses of marijuana as well in part to address the opioid epidemic. 128 To the extent that states expand their medical marijuana programs to address pain and treat OUDs, 129 marijuana is more than a potential substitution for opioids. It becomes a proposed partial solution to the prescription opioid epidemic. These state policies, however, are embroiled in legal and public health controversies. 130 From the federal perspective, the irony of using an illicit drug, marijuana, to remedy harms of lawful drugs, prescription opioids, is not likely lost on DOJ. New York's proposed policy to recreationalize marijuana specifically to address opioid morbidity and mortality could be especially egregious. Although federal laws and policies on the legality of marijuana are shifting to better reflect public sentiments and states' permissive approaches, 131 they do not currently align.
Resulting federal prosecutions, sanctions, and prohibitions may still follow.
One such prohibition relates to insurance coverage. Since marijuana remains an illicit, Schedule I drug, federally-funded health insurers (e.g. Medicare, Medicaid, VA, Indian Health Service) and substance abuse providers cannot pay for or reimburse costs of medical marijuana uses. 132 Consequently, limited insurance coverage for medical cannabis can make it more expensive to treat pain than cheaper prescription opioids covered by insurers. 133 Use of marijuana to address OUDs is essentially banned from federal reimbursement. Providers and patients seeking medicinal uses of marijuana may thus have to rely on many patients' capacities to self-fund the medications. As with many other medical injustices, patients of lower socioeconomic statuses (or living in places not authorizing medical marijuana) may lack access to refined medical marijuana products.
Patients turning to unregulated synthetic cannabinoids instead risk ingesting products laced with deadly synthetic opioids like fentanyl. 134 The dual policy premise that substituting marijuana for opioids provides an effective and failsafe way for Americans to simultaneously treat pain and derail drug misuse is challengeable. One longitudinal study identified continued opioid use and lower self-efficacy regarding one's ability to manage pain in patients using long-term cannabis. 135 If these findings are further validated, marijuana may provide minimal or no effectiveness in permanently weaning chronic pain patients off opioids. The National Academies found (1) moderate evidence of a correlation between cannabis use and developing substance use disorders and (2) limited evidence on how marijuana use affects patients' use of other substances. 136 These trends suggest that marijuana use may predispose individuals to substance use disorders and contraindicate the promotion of medical cannabis to stem OUDs. Unfortunately, further research on the long-term clinical impacts of cannabis is confounded by federal regulatory and funding limitations.
137
From a public health point of view, transferring population health risks of one primary class of drugs (opioids) to another (marijuana) seems innocuous at first glance. As noted, the goal of saving lives otherwise lost to opioids should dominate decision-making (although some may disagree on utilitarian grounds). In the fervor to save tens of thousands of lives, however, is the potential to negatively impact the short-and long-term health of millions of Americans via known and unknown effects of marijuana use. 138 As the epidemic wave of opioidrelated morbidity and mortality predictably lessens, resulting adverse effects of marijuana use, especially among younger Americans, could swell in the years ahead. This might very well be a trade-off worth making if only public health impacts of long-term cannabis use across populations were better understood.
CONCLUSION
Exiting the long, horrid tunnel of deaths and morbidity tied to the twenty-plus year opioid epidemic, the forward view is promising. Affirmative interventions to stymie prescription opioids and their abuse are being undertaken. Corporate accountability is unfolding. Real changes in practitioner and patient understanding and behaviors are emerging. Still, the road ahead is cloudy. Treating Americans' pain remains a priority, but suitable opioid alternatives are few. Marijuana emerges as an obvious choice of multiple state policy-makers. It is relatively inexpensive, available lawfully in most states, comes in many forms, and is increasingly supported by the public for medicinal uses. However, greater uptake of marijuana, even purely for medicinal purposes, faces significant legal hurdles and an uphill climb concerning proof of efficacy to address pain or opioid use disorders. Public health and safety risks of long-term marijuana use, especially among younger generations, represent more than a slight curve in the road. With relatively little known under current surveillance and research, these hazards may constitute the next mountainous epidemic the nation must ascend.
